Individualizing Early-Stage HER2-Positive Breast Cancer

As more agents become approved, it ’s important to individualize therapy for this patient population, Sara A. Hurvitz, MD, said at the 37th Annual Miami Breast Cancer Conference.

Source: CancerNetwork - March 6, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news